Japan’s Kyowa Hakko Sells Amgen Drug Rights For $520 Million
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kogyo has agreed to sell the rights to a key cancer and inflammation drug it is developing to Amgen for $520 million. The U.S. biotech is to pay Japan's Kyowa $100 million up-front and the rest during development of humanized monoclonal antibody KW-0761. Under the arrangement, Kyowa subsidiary Kirin Holdings is to retain rights to develop and sell the drug in Japan, South Korea, China and Taiwan, and Amgen elsewhere in the world. The drug is in Phase I trials on lymphoma patients. (Click here for more
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.